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Abstract
Background: Limiting treatment forms part of practice in many fields of medicine. There is a scarcity of robust
data from Germany. Therefore, in this paper, we report results of a survey among German physicians with a focus
on frequencies, aspects of decision making and determinants of limiting treatment with expected or intended
shortening of life.
Methods: Postal survey among a random sample of physicians working in the area of five German state chambers
of physicians using a modified version of the questionnaire of the EURELD Consortium. Information requested
referred to the patients who died most recently within the last 12 months. Logistic regression was performed to
analyse associations between characteristics of physicians and patients regarding limitation of treatment with
expected or intended shortening of life.
Results: As reported elsewhere, 734 physicians responded (response rate 36.9%) and of these, 174 (43.2%) reported
a withholding and 144 (35.7%) a withdrawal of treatment. Eighty one physicians estimated that there was at least
some shortening of life as a consequence. In 25.9% of these cases hastening death had been discussed with the
patient at the time or immediately prior to this action. Types of treatment most frequently limited was artificial
nutrition (n = 35). Bivariate analysis indicates that limitation of treatment with possible or intended shortening of
life for patients aged > 75 years is performed significantly more often (p = 0.007, OR 1.848). There was significantly
less limitation of treatment in patients who died from cancer compared to patients with other causes of death
(p = 0.01, OR 0.486). There was no significant statistical association with physicians’ religion, palliative care
qualification or frequencies of limiting treatment.
Conclusions: In comparison to recent research from other European countries, limitation of treatment with
expected or intended shortening of life is frequently performed amongst the investigated sample. The role of
clinical and non-medical aspects possibly relevant for physicians’ decision about withholding or withdrawal of
treatment with possible or intended shortening of life and reasons for non-involvement of patients should be
explored in more detail by means of mixed method and interdisciplinary empirical-ethical analysis.
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Background
Limiting treatment, in the sense of withholding and/or
withdrawal of medical measures, is part of clinical prac-
tice across different fields of medicine [1–5]. At the
same time, there is considerable variation in frequency.
More than a decade ago, the EURELD study, for ex-
ample, showed a frequency of 4% in Italy, while physi-
cians in Switzerland reported limitation of treatment in
28% of cases [6]. In addition, there have been changes
observed over time with regard to the frequency of
these decisions [1, 7, 8].
Although accepted in many jurisdictions, limitation of
treatment is still challenging for physicians [9–11]. There
is evidence that decisions about the intensity of treatment
in patients near the end of life vary considerably and that
these variations cannot be explained fully by medical fac-
tors [12–14]. Qualitative studies [15] and survey research
suggest that physicians’ values and other non-medical
factors contribute to the variation in practice [16–18].
While the practice of limiting treatment has been
researched in several countries [1, 19, 20], there is a
scarcity of robust data in Germany. Parts of the data
gathered in Germany more recently are difficult to in-
terpret due to the vague terminology used for capturing
the different end-of-life practices [21]. Other studies
are limited to particular clinical fields, such as palliative
care, intensive care or oncology [3, 22–24]. Further-
more, some of the data on limitation of treatment near
the end of life available were gathered almost two de-
cades ago [25, 26]. In the light of the changes regarding
the ethico-legal framework for decisions at the end of
life [27], it is possible that the frequency of (some of
the end-of-life practices) or reporting of the practice
changes over time. This might be particularly the case
given the fact that limitation of treatment with possible
shortening of life has gained particular scientific and
public interest in Germany in the course of the debate
about legislating advance directives. While the German
courts had confirmed patients’ right to reject treatment
decades ago, legislation which confirms patients’ right
to limit any treatment in advance has only been in
existence since 2009.
The right of a patient to reject treatment is an important
normative cornerstone. However, decisions about limiting
treatment are often discussed in daily clinical practice in
situations in which patients are open to more treatment,
but in which the benefit and harm of specific treatment
needs to be evaluated critically. In addition to the clinical
challenge to determine benefit and harm in the light of
frequent absence of evidence in such situations, there are
also ethically relevant challenges. How far physicians can
evaluate the benefit and harm of treatment without taking
into account the subjective perspective of the patient, for
example, is a matter for debate.
Data about frequencies and characteristics of decisions
about limiting treatment and the decision-making
process are important to identify challenges and to in-
form guidance on good clinical practice with regard to
these decisions. The data which has been elicited in rep-
resentative studies in various countries [1, 6–8, 28, 29]
cannot necessarily be transferred to the situation in
Germany. This is because country-specific, cultural and
legal differences may not only influence the findings, but
also the interpretation of findings regarding guidance on
good clinical practice concerning limiting treatment.
The aim of this paper is to provide an in depth empirical
analysis of practices of treatment limitation. We present
findings on limiting treatment collected in a survey of
physicians in five state chambers of physicians in Germany
in 2013. The analysis focuses on those practices in which
responding physicians expected or intended shortening
of life. The empirical findings will be interpreted in the
light of available international survey research and with
reference to ethical and legal standards relevant for
decisions about withholding or withdrawal of treatment
in Germany.
Methods
Participants and mailing procedure
The authors conducted a postal cross-sectional survey
on end-of-life practices among a random sample of
2,003 physicians from five German state chambers of
physicians (Westphalia-Lippe, North Rhine, Saarland,
Saxony and Thuringia), which cover around a third of
all physicians working in Germany. The methods and
first findings regarding the range of different end-of-life
practices have been published elsewhere [30]. In line
with the procedure approved by the Research Ethics
Committee of the Medical Faculty of the Ruhr-University
Bochum (AZ 4196–11) there was no identifying code on
the questionnaire for the protection of anonymity. Physi-
cians received the questionnaire and a leaflet with infor-
mation on purpose, potential benefits and risks of the
study as well as research procedure for the first time in
the second calendar week of 2013. Consent was taken
for granted when physicians returned the questionnaire
anonymously. All physicians received a reminder and a
second questionnaire in calendar week four, together
with the information that only one questionnaire should
be returned by each physician. Due to the procedure, it
was not possible to conduct a non-responder analysis.
Questionnaire
We used a modified version of the EURELD question-
naire, which had already been used in the German-
speaking part of Switzerland [6] and in an earlier study on
end-of-life practices of German palliative care physicians
conducted by the second and last author of this paper,
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as the survey instrument [3, 22]. Changes that were
made were distinctions of questions on actions from
expected or intended effects [31] and three additional
questions on physicians’ views of assisted suicide. Fol-
lowing the procedure described by Seale [31], potential
participants had been informed on the first page of the
questionnaire that all questions of the survey instru-
ment refer to the patient who had most recently died
under their care. Participants of the study who indi-
cated on the cover page of the questionnaire that they
had not cared for a dying patient within the last
12 months were asked to return the questionnaire with
information only on their views on assisted suicide and
socio-demographic aspects. Completed questionnaires
were sent to a scientific institute for social research
which recorded the data in a SPSS data file to avoid any
direct contact between respondents and researchers.
The relevant key questions can be found in Table 1.
Analyses
The raw data entry was double-checked within this insti-
tution. In addition, the plausibility of the data entered
was checked by the first author. Free text comments re-
garding the type of treatment that had been limited were
categorised by the first author together with the last
author by means of a modified categorical system of
different types of treatment which had been used in
earlier research [3, 29]. Table 2 indicates the different
steps of the analysis and the respective sample.
The results of the descriptive analysis of end-of-life
practices are provided as total numbers and valid per-
centages for the total sample or subgroups. Statistical
analysis was performed with IBM SPSS Statistics version
23.0 for Windows. We explored associations between
the limitation of medical treatment and characteristics
from the side of the patient or the physician based on
findings of earlier surveys [29, 32]. This included the
possible influence of patients’ age [3, 33, 34], disease
[3, 35], physicians’ religious affiliation [16] and special-
isation in palliative care [3] with regard to limiting
treatment with possible and/or intended shortening of
life using binary logistic regression. Our hypotheses
were as follows: a) treatment limitation with possible
or expected shortening of life is performed more often
in patients of older age; b) treatment limitation with
possible or expected shortening of life is performed
less often in patients dying from cancer; c) physicians
who describe themselves as religious perform less
treatment limitation with a possible or expected short-
ening of life than physicians who are non-religious;
and d) physicians with a specialisation in palliative care
perform treatment limitation with a possible or ex-
pected shortening of life more often than other med-
ical specialists. Binary logistic regression was used to
explore bivariate relationships between the dependent
variable ‘treatment limitation with possible and/or
intended shortening of life’ and four independent
variables: (1) dichotomised patient’s age ≥ 75 years, (2)
patient dying from cancer, (3) physician being reli-
gious, and (4) physician’s specialisation in palliative
medicine. Odds ratios (ORs) and their 95% confidence
intervals (CI) were computed. Subsequently, a multi-
variable logistic regression was performed with the
aforementioned categories in one block using the enter
method. P-values < 0.05 were considered significant.
Results
As reported elsewhere [30], a sample of 734 respondents
(response rate 36.9%) was obtained. A total of 403
physicians within this sample had cared for an adult
patient who died within the 12 months prior to the
survey. Of those physicians who had cared for a patient
near the end of life, 219 (54.34%) reported a limitation
of treatment. Of these, 174 (43.2%) reported a with-
holding and 144 (35.7%) a withdrawal of treatment
(doctors could have both withheld and withdrawn
treatment in the same patient). In the following, we re-
port unpublished data of an in-depth analysis of deter-
minants for limiting treatment and characteristics of
the decision-making process.
Types of limited treatment and expected consequences
regarding shortening of life
Withholding or withdrawing of treatment with a pos-
sible or intended shortening of life was performed in
144/403 cases (35.7%). 135 physicians (33.5%) have
Table 1 Key questions relevant for statistical analysis
(1) “Did you or another physician perform or did you make sure that
one of the following actions would be performed: a) Withholding of
treatment b) Withdrawing of treatment.”
(2) In case of withholding/withdrawing a treatment: “Did you or another
physician assume that this action will probably or certainly hasten
the death of the patient?”
(3) “Was death the consequence of withholding/withdrawing a
treatment with the explicit intention to hasten death?”
Due to the structure of the questionnaire, we were only able to analyse
the decision-making for the decisions on treatment limitation that were
the limitations mentioned last and, therefore, the most important.
Table 2 Different steps of analysis and sample size
(1) Analysis of the whole sample regarding the frequency of limiting
treatment as one aspect of end-of-life practices (n = 403)
(2) Analysis of the subgroup concerning “Types of limited treatment and
expected consequences” (n = 104)
(3) Analysis of the subgroup “Decision-making and patient involvement”
(n = 81)
(4) Regression analysis on determinants associated with limitation of
treatment and expected shortening of life (n = 403)
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performed a treatment limitation with a possible short-
ening of life and 19.1% (n = 77) with the explicit
intention to shorten life (doctors could have had
ambivalent intentions). As mentioned in the methods
section and due to the structure of the questionnaire,
details of decisions about withholding or withdrawal of
treatment could only be further analysed if respondents
indicated this type of end-of-life practice as the last in a
row of several practices (e.g. symptom alleviation,
assisted suicide) on the questionnaire. Accordingly, we
could analyse in more detail the data of 75 patients for
whom treatment limitation with intended shortening of
life and 29 patients for whom limiting treatment with
possible shortening of life (but no respective intention)
was reported (step 2 of analysis; see method section).
The characteristics of the 104 physicians who limited
treatment and respective patient characteristics can be
found in Tables 3 and 4.
Out of the subsample defined above, 41 physicians of
the 104 respondents (40.6%) estimated the shortening of
life as a consequence of limiting treatment to be
between 1 and 7 days. A total of 20 physicians (19.8%)
estimated that there was no shortening of life in the
concrete patient as a consequence of their action. In
ten cases (9.9%), shortening of life was estimated to be
between 1 and 6 months. In this group, it was reported
that six patients had died from cancer, two from cardio-
vascular diseases and two from other or unknown dis-
eases. Table 5 summarises the findings on estimated
shortening of life as a consequence of limiting treat-
ment. The types of treatment limited most frequently
were artificial nutrition (n = 35), antibiotics (n = 33) and
the administration of catecholamines (n = 27). Table 6
summarises the data reported on types of treatments
which had been withheld or withdrawn.
Decision-making and patient involvement
Eighty one physicians estimated that there was at least
some shortening of life as a consequence of the limita-
tion of treatment (see Table 5). This sample is a sub-
group of the cases with intended or possible shortening
of life (n = 104) reported above. A total of 21 of the
physicians in this subsample (25.9%) reported that has-
tening death as a possible or intended consequence of
limiting treatment had been discussed with the patient
at the time or immediately prior to this action (see
Table 7). In 23 cases (28.4%), the action was discussed
with the patient some time before. In 37 cases (45.7%),
the estimated hastening of death due to the limitation
of treatment performed was not discussed with the pa-
tient at all. In 29 of these cases (78.4%), the patient
was considered as not able to evaluate his/her situation
and make an adequate decision about it at all by the
physician.
In six cases (16.2%), the patient was judged as not
entirely able to evaluate his/her situation. In two cases
Table 3 Characteristics of study participants n = 104
N = 95 Percent
Medical specialty
Internal medicine 25 26.3
General medicine 20 21.1
Anaesthesia 19 20.0
Surgery 17 17.9
Neurology/Psychiatry 7 7.4
Emergency medicine 2 2.1
Gynaecology 2 2.1
Otolaryngology 2 2.1
Urology 1 1.1
Missing data 9 –
Age
< 36 years 29 27.9
36–45 years 29 27.9
46–55 years 24 23.1
56–65 years 17 16.3
> 65 years 5 4.8
Gender
Male 64 61.5
Female 40 38.5
Religion
Protestant 40 38.5
Catholic 39 37.5
No religion 19 18.3
Islamic 2 1.9
Other 4 3.8
Table 4 Patient characteristics n = 104
Number Percent
Age
< 75 years 34 32.7
≥ 75 years 70 67.3
Gender
Male 54 52.4
Female 49 47.6
Cause of deatha
Cancer 36 34.6
Cardiovascular disease 27 26.0
Disease of the nervous system 16 15.4
Respiratory disease 9 8.7
Other/Unknown 21 20.2
amultiple answers possible
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(5.4%), the patient was judged able to evaluate the situ-
ation properly. In one of these cases, “dementia” was
given as a reason for not discussing hastening of death,
in the other, no specific reason was indicated for not
discussing limitation of treatment with hastening death
as a possible consequence.
Determinants associated with limitation of treatment and
expected shortening of life
Based on our hypotheses (see method section), we inves-
tigated possible associations between patient disease
(cancer versus non-cancer), age and physicians’ religious
affiliation and specialisation in palliative medicine with
frequencies of limiting treatment with shortening life.
Bivariate analysis shows that age ≥ 75 years is signifi-
cantly associated with limiting treatment with a possible
and/or intended shortening of life (p = 0.007, OR 1.848,
CI [1.183;2.886]). However, this association could not
be affirmed in multivariable regression which included
patient disease (cancer versus non-cancer), physicians’
religious affiliation and specialisation in palliative medi-
cine (p = 0.205, OR 1.432, CI [0.822;2.496]). Compared
to patients dying from other diseases, limitation of treat-
ment at the end of life in patients dying from cancer was
performed significantly less often (bivariate analysis: p =
0.000, OR 0.409, CI [0.261;0.64], multivariable analysis:
p = 0.01, OR 0.486, CI [0.281;0.84]). There were no
statistically significant differences regarding the per-
formance of treatment limitation between physicians
with and without religious affiliation (bivariate regres-
sion: p = 0.951, OR 0.984, CI [0.581;1.666], multivariable
regression: p = 0.829, OR 1.072, CI [0.572;2.011]). There
was also no significant association between the physician
being specialised in palliative care and limiting treatment
with possible or intended shortening of life (bivariate re-
gression: p = 0.440, OR 0.742, CI [0.348;1.583], multivar-
iable regression: p = 0.727, OR 0.866, CI [0.386;1.943]).
Table 8 summarises the findings of bi- and multivariable
logistic regression analysis regarding the association of
Table 5 Expected shortening of life reported by physicians who limited treatment
Action and consequence:
Time of estimated shortening of life
Limiting treatment with intended
shortening of life (n = 75)
Limiting treatment with possible
shortening of life (n = 29)
Total Withholding Withdrawing Total Withholding Withdrawing
N %a N % N % N %a N % N %
1–6 months 10 13.7 6 12.5 4 16.0 – – – – – –
1–4 weeks 14 19.2 8 16.7 6 24.0 3 10.7 2 13.3 1 7.7
1–7 days 32 43.8 22 45.8 10 40.0 9 32.1 7 46.7 2 15.4
<24 h 9 12.3 8 16.7 1 4.0 4 14.3 – – 4 30.8
Not shortened at all 8 11.0 4 8.3 4 16.0 12 42.9 6 40.0 6 46.2
Missing data 2 – 2 – – – 1 – – – 1 –
aPercentages refer to valid responses (n = 73 for limiting treatment with intended shortening of life and n = 28 for limiting treatment with possible shortening of life)
Table 6 Number of patients (n = 104) and types of limited
treatment which was withheld and/or withdrawna
Withholding of treatment Withdrawal of treatment
(n = 87) (n = 60)
N % N %
Nutrition 22 25.3 13 21.7
Antibiotics 19 21.8 14 23.3
Catecholamines 15 17.2 12 20.0
Hydration 15 17.2 11 18.3
Dialysis 14 16.1 9 15.0
Respiration 14 16.1 5 8.3
Chemotherapy 12 13.8 8 13.3
Resuscitation 9 10.3 7 11.7
Medicationb 8 9.2 15 25.0
Intubation 6 6.9 - -
Other 4 4.6 2 3.3
Surgery 4 4.6 1 1.7
Diagnostic tests 3 3.4 - -
Radiotherapy 2 2.3 1 1.7
Hospital admission 2 2.3 - -
Transfusions 1 1.1 1 1.7
amultiple answers possible
bother than antibiotics, chemotherapy and catecholamines
Table 7 Questions concerning the end-of-life discussion
Has the possible or intended shortening of life been
discussed with the patient?
Number Percent
- Yes, at the time or shortly before this action 21 25.9
- Yes, some time before 23 28.4
At the time of discussion: Did you consider the patient able to evaluate
his/her situation properly and to take a competent decision?
- Yes, the patient was able to do so 34 77.3
- No, not entirely able to do so 8 18.2
- No, not able at all 2 4.5
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socio-demographic factors of patients and physicians
with a prevalence for limiting treatment with possible or
intended shortening of life.
Discussion
This paper provides in-depth analyses of practices and
decision-making about limiting treatment of German
physicians in those cases in which shortening of life was
expected or even intended by the treating physician. The
study contributes data elicited with an internationally
widely used survey instrument [6, 8, 29] from a sample
of German physicians who work in different clinical
fields. In the following, we will compare the findings
with data elicited in other countries and analyse the
results against the background of current ethical and
legal guidance in Germany.
Frequency of limiting treatment
Practices of limitation of treatment with intended or
possible shortening of life in our sample are the second
most frequent decisions at the end of life (n = 144,
35.7%). Withholding or withdrawal of medical measures
with intended or possible shortening of life takes place
less often than alleviation of symptoms (n = 299, 86.7%),
but more often than “palliative sedation” (n = 105,
30.8%) or the much discussed practices of physician-
assisted suicide (n = 1, 0.3%) and euthanasia (n = 2, 0.6%)
[30]. Given that the survey instrument, similar to the
study from Seale [36], clearly distinguishes questions on
the actual practice (e.g. withholding or withdrawing)
from actions with expected consequences or the intention
of the physician (i.e. shortening of life), we believe that the
survey instrument avoids misunderstandings and that the
figures gathered are robust [37, 38]. Compared to the
study published by Seale in 2009 [36], treatment limitation
with intended shortening of life (19.1 vs. 7.4%) as well
as with possible shortening of life (33.5 vs. 28.9%) was
practiced more frequently in our sample. Moreover, our
figures are comparable to data published recently by
Bosshard et al. in Switzerland [7] as well as the data
presented by Onwuteaka et al. in the Netherlands [8].
Compared to the data published by Chambaere et al.
[1] withholding and withdrawing of life-prolonging
treatment was performed more frequently in our sam-
ple. However, the latter three studies do not distinguish
between data about the practice (“limiting treatment”)
and the practice combined with a consequence (“limit-
ing treatment with possible shortening of life”) which
means that comparison is limited. In addition, the dif-
ferences in methodology such as the chosen approach
to physicians based on death certificates signed by the
respective physicians in the aforementioned three stud-
ies should be considered as a factor relevant for the
reported differences.
Moreover, our results have to be interpreted with
caution due to potential selection bias in a sample in
which more than 60% of physicians did not respond.
One explanation for the relatively high rate of limiting
treatment may be an increased awareness of the possi-
bility of limiting treatment lawfully in Germany if this
is in accordance with the patients will. Debates around
the legislation of advance directives (enacted) and the
more recent debate about a law on assisted suicide
(enacted in 2015) during which the normative frame-
work for limiting treatment at the end of life has been
reiterated in many scientific and popular articles may
be triggers for such an increased awareness. In this re-
spect the reported high numbers of limiting treatment
could be interpreted as positive effects of the debate in
the sense of an increased awareness amongst physicians
that limiting treatment is an essential part of high quality
care at the end of life.
Decision-making and patient involvement
How far patients are involved in decisions about limiting
treatment with associated shortening of life is of particular
interest from a clinical-ethics perspective. This is because
the normative evaluation of benefit and harm of a treat-
ment against possible shortening of life is a matter which
varies according to personal values and preferences. Ac-
cordingly, the involvement of patient in such evaluation
can inform a decision which takes into account the
patients’ personal stance. The responses of the physicians
indicate that in about half of the cases, decisions about
limiting and the consequence of possible or intended
hastening death had been discussed with the patient at
least some time prior to the actual limiting of treatment.
Evidence indicates that the time of discussing end-of-life
issues depends on perceived competences and further
characteristics from the side of the physician [39, 40]. In
Table 8 Results of logistic regression on patients’/physicians’ characteristics and limiting treatment (n = 403)
Treatment limitation with possible/intended shortening of life
Socio-demographic factors Bivariate logistic regression Multivariable regression
Patient age ≥ 75 years p = 0.007, OR 1.848, CI [1.183;2.886] p = 0.205, OR 1.432, CI [0.822;2.496]
Patient dying from cancer p = 0.000, OR 0.409, CI [0.261;0.64] p = 0.01, OR 0.486, CI [0.281;0.84]
Physician being non-religious p = 0.951, OR 0.984, CI [0.581;1.666] p = 0.829, OR 1.072, CI [0.572;2.011]
Physician’s specialisation in palliative medicine p = 0.440, OR 0.742, CI [0.348;1.583] p = 0.727, OR 0.866, CI [0.386;1.943]
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the group in which there had not been a discussion with
patients, this has been explained by the respondents with
reference to the physicians’ judgment that the patient was
deemed not able to make a competent decision. The high
number of cases in which decisions about limiting treat-
ment with shortening of life are being made on behalf of
incompetent patients point to the importance of commu-
nicating options and preferences early, as this is advocated
by proponents of advance care planning [41, 42] which
has been recently incorporated as part of the German
legislation on hospice and palliative care (Gesetz zur
Verbesserung der Hospiz- und Palliativversorgung in
Deutschland, 8.12.2015).
Clinical and non-medical determinants in limiting treatment
The statistical analysis of determinants associated with
decisions about limiting treatment with possible or
intended shortening of life confirms, as part of the bi-
variate analysis, earlier findings that there is signifi-
cantly more limiting of treatment with possible and/or
intended shortening of life in older patients [3, 33, 34].
However, logistic regression also indicates that there
are further factors possibly relevant to these decisions.
The relatively high number of (younger) cancer patients
in the sample in whom there is significantly less treat-
ment limitation may be a confounding factor respon-
sible for the fact that the association between age and
treatment limitation could not be confirmed in the
multivariable analysis. From a clinical perspective, a
higher prevalence of treatment limitation in elderly pa-
tients is of little surprise, since older age is often associ-
ated with a worse health condition which restricts
treatment options. Furthermore, there is a lack of evi-
dence for the effects of treatment in elderly patients,
since these patients are often underrepresented in clin-
ical research [43]. However, quantitative and qualitative
research raise questions whether “biological age”, in the
sense of fitness, is the only reason for treating elderly
patients less intensively. Findings from qualitative inter-
views with oncologists in Germany and the UK suggest
that images or stereotypes of the situation of younger
or elderly patients may influence decisions about offer-
ing or limiting cancer treatment [18, 44]. There may be
a risk of both overtreatment of younger as well as
undertreatment of older patients if health professionals
do not reflect that the evaluation of life situations of
younger or older patients may be value-laden. Our
research did not confirm our hypotheses regarding the
influence of the physicians’ religious affiliation or spe-
cialisation in palliative care with the frequency of this
practice. Regarding the possible influences of the reli-
gion of the physician, our findings seem to be in con-
trast with those of Seale [16], who found that doctors
who described themselves as non-religious more often
made decisions with foreseen or intended ending of life.
However, one explanation for this difference may be
that our survey instrument did not explicitly investigate
perceived religious attitudes, but only formal affiliation.
With regard to the lack of an association between limiting
treatment and physicians’ additional qualification in pallia-
tive care, one explanation is the low number of physicians
in our sample who had such a qualification (n = 33) and
the over-representation of patients with cancer.
Limitations and strengths
The refusal of the majority of the state chambers of physi-
cians to draw a random sample for this study and the low
response rate of 36.9% are limitations with regard to the
representativeness of the sample of physicians participat-
ing. Another limitation is the possible misunderstanding
of single questions given the complex topic surveyed in
this study [11]. Further limitations encompass socially de-
sirable answers and recall bias. A strength of the study is
the use of an internationally widely used instrument with
a language which avoids misleading terms, such as “pas-
sive euthanasia”. Furthermore, the study is not limited to
selected fields, but reports findings from across different
clinical practices. Finally, the interpretation of data is a
result of multidisciplinary work involving philosophers,
health researchers and authors with clinical experience in
end-of-life care.
Conclusions
Limitation of treatment with expected and intended has-
tening death is, compared to international research, fre-
quently practiced in this sample of German physicians.
Clinical aspects (i.e. cancer) and socio-demographic
characteristics on the side of patients, for instance, seem
to influence decisions about limitation of treatment with
associated shortening of life. To be able to understand
how far these factors influence decisions about limiting
treatment with associated shortening of life using an
empirical mixed-method approach, it is important to
combine empirical research with conceptual analysis
rooted, for example, in ethics or sociology.
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